Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 6, 2007 - Issue 6
Submit an article Journal homepage
420
Views
34
CrossRef citations to date
0
Altmetric
Review

The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia

Edoardo Spina Universiy of Messina, Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, Policlinico Universitario, Via Consolare Valeria, 98125 Messina, Italy +39 090 221 3647; +39 090 221 3300; [email protected]; IRCCS Centro Neurolesi ‘Bonino-Pulejo’ , Messina, Italy
&
Roberto Cavallaro Vita Salute University Medical School, San Raffaele Scientific Institute Hospital, Department of Neuropsychiatric Sciences, Milan, Italy
Pages 651-662 | Published online: 30 Oct 2007

Bibliography

  • STAHL S: Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge university press, Cambridge, UK (2002).
  • NEWCOMER JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs (2005) 19(Suppl. 1):1-93.
  • YANG LPH, PLOSKER GL: Paliperidone extended release. CNS Drugs (2007) 21:417-425.
  • OWEN RT: Extended-release paliperidone: efficacy, safety and tolerability profile of a new antipsychotic. Drugs Today (2007) 43:249-258.
  • CITROME L: Paliperidone: quo vadis? Int. J. Clin. Pract. (2007) 61:653-662.
  • NO AUTHORS LISTED: Paliperidone (Invega) for schizophrenia. Med. Lett. Drugs Ther. (2007) 49:21.
  • KANE J, CANAS F, KRAMER M et al.: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. (2007) 90:147-161.
  • DAVIDSON M, EMSLEY R, KRAMER M et al.: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER). Results of a 6-week, randomized, placebo-controlled study. Schizophr. Res. (2007) 93:117-130.
  • MARDER SR, KRAMER M, FORD L et al.: Efficacy and safety of paliperidone extended-release tablets. Results of a 6-week, randomized, placebo-controlled study. Biol. Psychiatry (2007) (In Press).
  • KRAMER M, SIMPSON G, MACIULIS V et al.: Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. (2007) 27:6-14.
  • INVEGA (PALIPERIDONE) EXTENDED-RELEASE TABLETS: Prescribing information. Janssen LP, Titusville, NJ, USA (2006).
  • CONLEY R, GUPTA SK, SATHYAN G: Clinical spectrum of the osmotic-controlled release oral delivery system (OROS*), an advanced oral delivery form. Curr. Med. Res. Opin. (2006) 22:1879-1892.
  • KEITH S: Advances in psychotropic formulations. Prog. NeuroPsychopharmacol. Biol. Psychiatry (2006) 30:996-1008.
  • BASS DM, PREVO M, WAXMAN DS: Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS): a retrospective study. Drug Saf. (2002) 25:1021-1033.
  • MEGENS AA, AWOUTERS FH, SCHOTTE A et al.: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (1994) 114:9-23.
  • LEYSEN JE, JANSSEN PM, MEGENS AA, SCHOTTE A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry (1994) 55(Suppl.):5-12.
  • SCHOTTE A, JANSSEN PF, GOMMEREN W et al.: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (1996) 124:57-73.
  • SEEMAN P: An update of fast-off dopamine D2 atypical antipsychotics. Am. J. Psychiatry (2005) 162:1984-1985.
  • BOWDEN CR, VOINA SJ, WOESTENBORGHS R, DE COSTER R, HEYKANTS J: Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J. Pharmacol. Exp. Ther. (1992) 262:699-706.
  • KARLSSON P, DENCKER E, NYBERG S et al.: Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone ER in healthy subjects. Schizophr. Res. (2006) 81(Suppl. 1):85-86.
  • HUANG ML, VAN PEER A, WOESTENBORGHS R et al.: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. (1993) 54:257-268.
  • FANG J, BOURIN M, BAKER GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4. NaunynSchmiederberg's Arch. Pharmacol. (1999) 359:147-151.
  • YASUI-FURUKORI N, HIDESTRAND M, SPINA E, FACCIOLÁ G, SCORDO MG, TYBRING G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab. Dispos. (2001) 29:1263-1268.
  • SCORDO MG, SPINA E, FACCIOLÁ G, AVENOSO A, JOHANSSON I, DAHL ML: Cytochrome P450 2D6 genotype and steady-state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (1999) 147:300-305.
  • ROSSENU S, CRAUWELS H, CLETON A et al.: Evaluation of the pharmacokinetics of several formulations of paliperidone. AAPS J. (2006) 8(Suppl. 2): Abstract M1371.
  • CLETON A, ROSSENU S, TALLURI K et al.: Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone and an immediate-release formulation of risperidone. Clin. Pharmacol. Ther. (2007) 81(Suppl. 1):S63.
  • ROSSENU S, CRAUWELS H, CLETON A et al.: Extended-release formulation of paliperidone shows dose proportional pharmacokinetics. AAPS J. (2006) 8(Suppl. 2): Abstract T3123.
  • VAN BEIJSTERVELDT LE, GEERTS RJ, LEYSEN JE et al.: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (1994) 114:53-62.
  • ARAVAGIRI M, YUWILER A, MARDER SR: Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (1998) 139:356-363.
  • ARAVAGIRI M, MARDER SR: Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (2002) 159:424-431.
  • WANG JS, RUAN Y, TAYLOR RM, DONOVAN JL, MARKOWITZ JS, DE VANE CL: The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. (2004) 7:415-419.
  • EJSING TB, PEDERSEN AD, LINNET K: P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug–drug interaction experiments. Hum. Psychopharmacol. (2005) 20:493-500.
  • DORAN A, OBACH RS, SMITH BJ et al.: The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. (2005) 33:165-174.
  • VERMEIR M, BOOM S, NAESSENS I, TALLURI K, EERDEKENS M: Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Eur. Neuropsychopharmacol. (2006) 30:S191-S192.
  • THYSSEN A, CRAUWELS H, CLETON A et al.: Effects of hepatic impairment on the pharmacokinetics of paliperidone. 46th Annual Meeting New Clinical Drug Evaluation Unit, Boca Raton, Florida, USA (2006) (Abstract n. I-90).
  • THYSSEN A, CLETON A, VAN OSSELAER N et al.: Effects of renal impairment on the pharmacokinetic profile of paliperidone extended-release tablets. Clin. Pharmacol. Ther. (2007) 81(Suppl. 1):S63.
  • ROSSENU S, CLETON A, BOOM S, ALNABAWY A, TALLURI K, EERDEKENS M: Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects. Clin. Pharmacol. Ther. (2007) 81(Suppl. 1):S64.
  • SPINA E, DE LEON J: Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol. (2007) 100:4-22.
  • CLETON A, BERWAERTS J, VAN DE VLIET I et al.: A randomized, open-label, single-center, crossover study of the potential effects of paroxetine on the pharmacokinetics of a single dose of paliperidone extended-release tablets in healthy subjects. 160th Annual Meeting APA, San Diego, California, USA (2007): (Abstract NR500).
  • SPINA E, AVENOSO A, SCORDO MG et al.: Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J. Clin. Psychopharmacol. (2002) 22:419-423.
  • SPINA E, AVENOSO A, FACCIOLÁ G, SCORDO MG, ANCIONE M, MADIA A: Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther. Drug Monit. (2001) 23:223-227.
  • SAITO M, YASUI-FURUKORI N, NAKAGAMI T, FURUKORI H, KANEKO S: Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J. Clin. Psychopharmacol. (2005) 25:527-532.
  • JUNG SM, KIM KA, CHO HK et al.: Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin. Pharmacol. Ther. (2005) 78:520-528.
  • SPINA E, AVENOSO A, FACCIOLÁ G et al.: Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther. Drug Monit. (2000) 22:481-485.
  • ONO S, MIHARA K, SUZUKI A, KONDO T et al.: Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (2002) 162:50-54.
  • WANG JS, ZHU HJ, MARKOWITZ JS, DONOVAN JL, DE VANE CL: Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (2006) 187:415-423.
  • ZHU HJ, WANG JS, MARKOWITZ JS, DONOVAN JL, GIBSON BB, DE VANE CL: Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology (2007) 32:757-764.
  • EERDEKENS M, KRAMER M, MARTINEZ L, LANE R, LIM P, CANUSO C: Efficacy and tolerability of oral paliperidone extended release tablets in the treatment of acute schizophrenia: pooled data from three 52-week, open label extension studies. 11th International Congress on Schizophrenia Research, Colorado Springs, Colorado, USA. Schizophr. Bull. (2007) 33:429.
  • KNEGTERING R, BASELMANS P, CASTELEIN S, BOSKER F, BRUGGEMAN R, VAN DEN BOSCH RJ: Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry (2005) 162:1010-1012.
  • MELKERSSON KI: Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum. Psychopharmacol. (2006) 21:529-532.
  • PANDINA GJ, CANUSO CM, YOUSSEF E, KUJAWA M, MAHMOUD R: Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia. Hum. Psychopharmacol. (2007) 22:326-327.
  • MELKERSSON KI: Author's response. Hum. Psychopharmacol. (2007) 22:328.
  • KRAMER M, EERDEKENS M, LANE R, LIM P, SHERR J, PALUMBO J: Metabolic outcomes in terms of weight, glucose and lipid profiles in patients with schizophrenia treated with paliperidone extended-release for 52 weeks. 160th Annual Meeting APA, San Diego, California, USA (2007): Abstract NR498.
  • TZIMOS A, KRAMER M, FORD L, GASSMANN-MEYER C, LIM P, EERDEKENS M: A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. Int. J. Neuropsychopharmacol. (2006) 9:S155.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.